Breast cancer vaccines; A comprehensive and updated review

Pathol Res Pract. 2023 Aug 4;249:154735. doi: 10.1016/j.prp.2023.154735. Online ahead of print.ABSTRACTAccording to the International Agency for Research on Cancer, breast cancer is more common than lung cancer globally. By 2040, mortality from breast cancer will rise by 50% and 40%, respectively. Despite advances in chemotherapy, endocrine therapy, and HER2-targeted therapy, breast cancer metastases and recurrences remain challenging to treat. Cancer vaccines are an effective treatment option because they stimulate a long-lasting immune response that will eliminate tumor cells. In studies on the breast cancer vaccine, no appreciable advantages were discovered. A recent study claims that immune checkpoint inhibitors or anti-HER2 monoclonal antibodies may be used in vaccinations. This vaccination strengthens the immune system to fight off breast cancer cells. Clinical trials have been conducted on DNA, dendritic cells, and peptide-based breast cancer vaccines. Studies on the breast cancer vaccine have employed subcutaneous, intramuscular, and intradermal injections. Clinical studies have shown that these efforts have not been successful. Several factors might have slowed the development of a breast cancer vaccine. The complexity of the immune system makes it challenging to create cancer vaccines. Given the heterogeneity of breast cancer, there may be a need for different vaccination strategies. Despite these obstacles, research into breast cancer vaccines continues. Effective ...

Source: Pathology, Research and Practice - August 23, 2023 Category: Pathology Authors: Sulieman Ibraheem Shelash Al-Hawary Ebraheem Abdu Musad Saleh Nodirjon Akhmetovich Mamajanov Nataliya S Gilmanova Hashem O Alsaab Adel Alghamdi Shakeel Ahmed Ansari Ahmed Hussien Radie Alawady Ali Hashiem Alsaalamy Ahmed Jaber Ibrahim Source Type: research